Dupixent Asthma Drug Shows Promise in Treating COPD, Boosting Sanofi and Regeneron Shares
TL;DR
Sanofi and Regeneron's jointly developed asthma drug Dupixent has shown promise in treating COPD patients, according to new data from a phase three clinical trial. The drug reduced bad bouts of chronic obstructive pulmonary disease by 30% compared with a placebo over 52 weeks. Dupixent is already approved for asthma and some skin conditions, but it could become the first new treatment in over a decade for COPD. The trial enrolled COPD patients with type 2 inflammation, and those who received Dupixent showed improvements in lung function, quality of life, and respiratory symptoms. A second phase three trial of Dupixent in COPD is ongoing, with data expected in 2024.
- Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD CNBC
- Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data Reuters
- Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today Yahoo Finance
- REGN Stock And SNY Stock Hit A 'Home Run' In COPD Treatment Investor's Business Daily
- Sanofi and Regeneron's Dupixent comes up big in COPD trial FiercePharma
Want the full story? Read the original reporting
Read on CNBC